fintols

Johnson & Johnson vs Pfizer (JNJ vs PFE)

Both trade near 41x earnings; Johnson & Johnson grows sales faster (+5.9% vs -0.4%) and Johnson & Johnson keeps a 16% margin vs 6%. Data Nov 2026.

Quick answer

On today's data (November 19, 2026): Pfizer looks cheaper on P/E: 40.1x against 41.4x for Johnson & Johnson. Johnson & Johnson grows faster: sales +5.9% against -0.4% for Pfizer in the latest quarter. Johnson & Johnson has the better net margin: 16.2% against 6.3% for Pfizer.

This is a snapshot of the numbers, not a recommendation to buy or sell.

Analyze Johnson & Johnson freeAnalyze Pfizer free

Your first analysis is free with a free account, no card.

Short answer

On P/E as of November 19, 2026, Johnson & Johnson is the more expensive of the two: it trades at 41.4x its annual earnings against 40.1x for Pfizer. Johnson & Johnson reports two segments. Innovative Medicine, the larger, sells drugs such as Darzalex, Stelara, Tremfya, Erleada and Carvykti across oncology, immunology and neuroscience. Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev. What helps read that gap: Johnson & Johnson sales +5.9% against -0.4% for Pfizer in the latest quarter; net margin 16.2% against 6.3%; net debt for Johnson & Johnson: 0.8x EBITDA against 2.0x EBITDA. A higher P/E is not by itself a buy or a sell signal: it is a snapshot of today.

Johnson & Johnson (JNJ) and Pfizer (PFE) compete in healthcare and pharma. Here are Johnson & Johnson and Pfizer side by side with their real figures as of November 19, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Johnson & Johnson or Pfizer.

Johnson & Johnson vs Pfizer: the figures

FigureJohnson & JohnsonPfizer
Share price$272.70 (November 18, 2026)$28.06 (November 18, 2026)
Market cap$656.5 billion$159.9 billion
P/E (TTM)41.4x40.1x
Forward P/E23.5x9.5x
Revenue growth (quarter)+5.9%-0.4%
Net margin (TTM)16.2%6.3%
Net debt / EBITDA0.8x2.0x
Dividend yield1.97%6.13%
Beta0.200.30

Johnson & Johnson and Pfizer figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 19, 2026; N/A means that Johnson & Johnson or Pfizer figure is not available, and we never estimate it.

3 key differences between Johnson & Johnson and Pfizer

  1. Dividend: Pfizer yields 6.13% at today's price and Johnson & Johnson yields 1.97%.
  2. Profitability: for every 100 of sales, Johnson & Johnson keeps 16.2 as net profit and Pfizer keeps 6.3.
  3. Size: Johnson & Johnson is worth $656.5 billion on the stock market, about 4.1 times Pfizer ($159.9 billion).

Johnson & Johnson or Pfizer: which fits your profile

Neither Johnson & Johnson nor Pfizer wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.

Verdict: Johnson & Johnson or Pfizer?

Of the 6 comparable figures in the table, Johnson & Johnson stands out on 4 (sales growth, net margin, less debt over EBITDA and lower volatility (beta)) and Pfizer stands out on 2 (lower P/E and dividend yield). That does not name a winner between Johnson & Johnson and Pfizer: the table is a snapshot of today, not a forecast.

You are halfway through

Keep reading free.

Create your free account to continue reading “Johnson & Johnson vs Pfizer (JNJ vs PFE)”.

No card required

That easy

Three steps. Zero spreadsheets.

  1. 1Search a companyBy the name you know it: Apple, Inditex, Santander… ETFs too.
  2. 2Fintols does the homeworkIt reads the official filings, runs the numbers and writes the analysis for you.
  3. 3You analyze and decideWith the five answers clear, you decide. And you save the analysis to review it when the price moves.
Analyze any stock free
Analyze JNJ free